The story of Viagra, formerly marketed by copyright, presents a intricate case study for investors considering the pharmaceutical landscape . Although its initial success and generation of vast in earnings , the exclusivity lapse has opened the door for generic medications, significantly diminishing profit opportunities. This shift raises concerns